Simulations Plus

Simulations Plus Revenue per Share

Delisted·Oct 7, 2026

The Revenue per Share of Simulations Plus (SLP) as of Nov 11, 2026 is 3.92 USD. In the previous year, Revenue per Share was 3.45 USD — a change of 13.35% (higher).

Revenue per Share

3.92USD

YoY

13.35%

Last updated:

Revenue per Share of Simulations Plus is 2025 3.92 USD. Revenue per Share of Simulations Plus was 2024 3.45 USD. It decreases by 13.35% higher compared to the previous year.

The Simulations Plus Revenue per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
Date
Revenue per Share
Jan 1, 2023
2.94 USD
Jan 1, 2024
3.45 USD
Jan 1, 2025
3.92 USD
Jan 1, 2026 (e)
4.07 USD
Jan 1, 2027 (e)
4.27 USD
Jan 1, 2028 (e)
4.61 USD
Jan 1, 2029 (e)
5.14 USD
Jan 1, 2030 (e)
5.83 USD
The Simulations Plus Revenue per Share history
YEARRevenue per ShareYoY
est5.83USD+13.25%
est5.14USD+11.66%
est4.61USD+7.98%
est4.27USD+4.84%
est4.07USD+3.92%
3.92USD+13.35%
3.45USD+17.59%
2.94USD+13.50%
2.59USD+15.57%
2.24USD+12.01%
2.00USD+7.76%
1.86USD+12.57%
1.65USD+21.96%
1.35USD+17.81%
1.15USD+8.09%
1.06USD+58.34%
0.67USD+8.94%
0.62USD+6.58%
0.58USD+6.56%
0.54USD-16.42%
0.65USD+18.93%
0.55USD+6.46%
0.51USD+6.52%
0.48USD+40.34%
0.34USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Simulations Plus Stock analysis

What does Simulations Plus do? Simulations Plus Inc is a company that offers software and services for the pharmaceutical industry. The company was founded in 1996 by Dr. Walt Woltosz and is headquartered in Lancaster, California. Simulations Plus began with the development of GastroPlus, a software that simulates the effects of drugs in the body using mathematical models. This software quickly became an important tool for the pharmaceutical industry to improve the effectiveness and safety of medications. Simulations Plus's business model is based on providing high-quality software and services for the pharmaceutical industry. They offer a wide range of products aimed at improving the effectiveness and safety of drugs by optimizing drug development and design. These products include software for simulating and analyzing the pharmacokinetics and dynamics of medications, a model for detecting and avoiding potential life-threatening liver damage, a cloud-based platform for simplifying the work of scientists and researchers, and services to assist with regulatory affairs and obtaining product approvals. Simulations Plus is known for its high-quality products and excellent customer support, and their various divisions and products contribute to improving the effectiveness and safety of medications, ultimately promoting patient health. The translation of the text is: "Simulations Plus Inc is a company that offers software and services for the pharmaceutical industry. The company was founded in 1996 by Dr. Walt Woltosz and is headquartered in Lancaster, California. Simulations Plus began with the development of GastroPlus, a software that simulates the effects of drugs in the body using mathematical models. This software quickly became an important tool for the pharmaceutical industry to improve the effectiveness and safety of medications. Simulations Plus's business model is based on providing high-quality software and services for the pharmaceutical industry. They offer a wide range of products aimed at improving the effectiveness and safety of drugs by optimizing drug development and design. These products include software for simulating and analyzing the pharmacokinetics and dynamics of medications, a model for detecting and avoiding potential life-threatening liver damage, a cloud-based platform for simplifying the work of scientists and researchers, and services to assist with regulatory affairs and obtaining product approvals. Simulations Plus is known for its high-quality products and excellent customer support, and their various divisions and products contribute to improving the effectiveness and safety of medications, ultimately promoting patient health." Simulations Plus is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Simulations Plus stock

Revenue per Share of Simulations Plus is 3.92 USD in 2025.

Revenue per Share of Simulations Plus changed from 3.45 USD to 3.92 USD, representing a 13.35% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Revenue per Share Simulations Plus since 2006 – with annual values, charts, and detailed analysis.

Revenue per Share divides total revenue by shares outstanding, showing how much revenue each share represents.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Simulations Plus

All Key Metrics — Simulations Plus